ELCC 2019 | Combining checkpoint inhibitors with chemotherapy for NSCLC

Marina Garassino

Marina Garassino, MD, of National Cancer Institute of Milan, Milan, Italy, discusses the combined use of chemotherapy and immunotherapy for treating non-small cell lung cancer (NSCLC). Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Garassino reports that identifying the clinical characteristics that differentiate between different NSCLC patient groups will help decide whether single agent therapy or combined therapy would be most appropriate for them.

Share this video